Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Christopher Peetz Buys 9,070 Shares

Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Christopher Peetz purchased 9,070 shares of the stock in a transaction dated Monday, September 9th. The stock was bought at an average cost of $11.02 per share, with a total value of $99,951.40.

MIRM traded down $0.05 during trading on Wednesday, hitting $10.13. 3,576 shares of the company’s stock traded hands, compared to its average volume of 45,832. The business’s 50 day moving average is $13.15. Mirum Pharmaceuticals has a 12-month low of $9.25 and a 12-month high of $15.50.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Wednesday, August 28th. The company reported ($2.29) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($1.83). Equities analysts expect that Mirum Pharmaceuticals will post -2.14 earnings per share for the current fiscal year.



Several analysts recently commented on MIRM shares. Citigroup assumed coverage on shares of Mirum Pharmaceuticals in a research report on Monday, August 12th. They set a “buy” rating and a $21.00 price objective on the stock. Evercore ISI initiated coverage on shares of Mirum Pharmaceuticals in a research note on Monday, August 12th. They set an “outperform” rating and a $25.00 price objective for the company. Roth Capital initiated coverage on shares of Mirum Pharmaceuticals in a report on Monday, August 12th. They issued a “buy” rating and a $33.00 target price for the company. Guggenheim initiated coverage on shares of Mirum Pharmaceuticals in a research note on Monday, August 12th. They issued a “buy” rating and a $18.00 target price on the stock. Finally, Raymond James initiated coverage on shares of Mirum Pharmaceuticals in a research note on Monday, August 12th. They issued an “outperform” rating and a $28.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus target price of $25.00.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).

Further Reading: The Structure of a Futures Contract

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.